Development
GSK plc
GSK
$41.30
$0.441.08%
NYSE
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 4.16% | -1.91% | -4.65% | -3.98% | 6.77% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.16% | -1.91% | -4.65% | -3.98% | 6.77% |
| Cost of Revenue | -8.60% | -15.39% | -17.87% | -13.02% | 9.50% |
| Gross Profit | 10.52% | 5.05% | 2.27% | 0.67% | 5.46% |
| SG&A Expenses | 13.09% | 10.05% | 6.94% | 5.15% | 8.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -102.91% | -38.43% | -53.99% | 8.82% | -43.85% |
| Total Operating Expenses | 0.55% | -2.48% | -6.04% | -3.93% | 5.82% |
| Operating Income | 15.70% | -0.11% | -0.18% | -4.13% | 9.93% |
| Income Before Tax | 7.16% | 62.22% | 32.01% | 2.92% | 41.53% |
| Income Tax Expenses | 4.73% | 30.61% | 13.72% | 139.34% | 686.59% |
| Earnings from Continuing Operations | 7.52% | 67.08% | 34.84% | -4.64% | 26.38% |
| Earnings from Discontinued Operations | -- | -100.05% | 737.96% | 700.37% | 746.34% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 20.14% | -28.37% | 2.63% | 26.86% | -112.91% |
| Net Income | -65.88% | -56.73% | 201.07% | 148.42% | 197.06% |
| EBIT | 15.70% | -0.11% | -0.18% | -4.13% | 9.93% |
| EBITDA | 6.08% | -4.54% | -2.45% | 2.88% | 12.27% |
| EPS Basic | -66.07% | -56.94% | 199.57% | 147.05% | 195.21% |
| Normalized Basic EPS | 24.41% | -2.49% | 1.00% | -1.39% | 3.74% |
| EPS Diluted | -65.98% | -56.87% | 199.04% | 146.45% | 194.57% |
| Normalized Diluted EPS | 24.43% | -2.44% | 0.95% | -1.45% | 3.55% |
| Average Basic Shares Outstanding | 0.64% | 0.66% | 0.65% | 0.62% | 0.57% |
| Average Diluted Shares Outstanding | 0.59% | 0.63% | 0.69% | 0.67% | 0.78% |
| Dividend Per Share | -5.40% | -30.80% | -42.06% | -45.57% | -44.52% |
| Payout Ratio | 0.89% | 0.36% | -0.81% | -0.73% | -0.74% |